IN.PACT AV Access Randomized Trial: Japan Cohort Outcomes Through 12 Months.
Hiroaki HaruguchiKotaro SuemitsuNaoko IsogaiMasaaki MurakamiMasahiko FujiharaKazuhiro IwadohJeremiah MenkHiroko OokuboTomonari Ogawanull nullLevester KirkseySanjay MisraAngelo SantosChad LaurichOmran Abul-KhoudoudAdie FriedmanVincent GalloAhmed Kamel Abdel AalMel SharafuddinSreekumar MadasseryDavid DexterCharles JoelsSyed HussainSandeep BaglaJeffrey HullJohn RossJeffrey HoggardBret WiechmannNaveen AtrayRandy CooperNeghae MawlaFernando KafieKotaro SuemitsuNaoko IsogaiMasahiko FujiharaMasaaki MurakamiShohei FuchinoueKazuhiro IwadohTomonari OgawaAndrew HoldenKesaka WickremesekeraPublished in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2023)
In this post-hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared to PTA. This article is protected by copyright. All rights reserved.